Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept

Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?

(2010) Pierre Laurent-Puig et al.   CURRENT OPINION IN ONCOLOGY

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

(2009) S-W Han et al.   BRITISH JOURNAL OF CANCER

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction

(2008) Jaffer A. Ajani   CANCER

Gains and Amplifications of c-myc, EGFR, and 20.q13 Loci in the No Dysplasia-Dysplasia-Adenocarcinoma Sequence of Barrett's Esophagus

(2008) A. M. Rygiel et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number

(2008) M A Kim et al.   HISTOPATHOLOGY

Irinotecan Combined with 5-Fluorouracil and Leucovorin as Second-line Chemotherapy for Metastatic or Relapsed Gastric Cancer

(2008) M.-D. Seo et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy for metastatic gastric cancer: past, present, and future

(2008) Atsushi Ohtsu   JOURNAL OF GASTROENTEROLOGY

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

(2008) David Cunningham et al.   NEW ENGLAND JOURNAL OF MEDICINE

Administration of Cetuximab Every 2 Weeks in the Treatment of Metastatic Colorectal Cancer: An Effective, More Convenient Alternative to Weekly Administration?

(2008) J. Tabernero et al.   ONCOLOGIST